Streetbeat News

Analyst Ratings

FTV

JP Morgan analyst Stephen Tusa maintains an Overweight rating on Fortive (NYSE:FTV) and raises the price target from $83 to $87.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:26 pm

BN

JP Morgan analyst Kenneth Worthington maintains an Overweight rating on Brookfield (NYSE:BN) and raises the price target from $48 to $52.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:25 pm

BSX

JP Morgan analyst Robbie Marcus has maintained an Overweight rating on Boston Scientific (NYSE:BSX) and increased the price target from $60 to $72.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:24 pm

LFST

LifeStance Health's stock price has declined following a report by Hindenburg Research, which announced it has taken a short position in LFST.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:24 pm

BSX

Raymond James analyst Jayson Bedford has maintained a Strong Buy rating on Boston Scientific (NYSE:BSX) and increased the price target from $67 to $73.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:22 pm

AVY

JP Morgan analyst Jeffrey Zekaukas maintains an Overweight rating on Avery Dennison (NYSE:AVY) and raises the price target from $185 to $218.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:22 pm

EAT

Raymond James analyst Brian Vaccaro has maintained a Strong Buy rating on Brinker International (NYSE:EAT) and increased the price target from $45 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:20 pm

ASH

JP Morgan analyst Jeffrey Zekauskas has maintained an Underweight rating on Ashland (NYSE:ASH) while raising the price target from $70 to $88.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:20 pm

CB

Raymond James analyst C. Gregory Peters has maintained a Strong Buy rating on Chubb (NYSE:CB) and increased the price target from $270 to $285.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:19 pm

ALNY

JP Morgan analyst Jessica Fung has maintained a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and increased the price target from $150 to $170.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 2:16 pm